Ten weeks to live: A population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands

References

• Moller H, Linklater KM, Robinson D. A visual summary of the EUROCARE-4 results: A UK perspective. Br J Cancer 2009;101(Suppl 2):S110–4.
   PubMed Web of Science ®Google Scholar
• Lemmens VE, Bosscha K, van der Schelling G, Brenninkmeijer S, Coebergh JW, de Hingh IH. Improving outcome for patients with pancreatic cancer through centralization. Br J Surg 2011;98:1455–62.
   PubMed Web of Science ®Google Scholar
• Seufferlein T, Bachet JB, Van Cutsem E, Rougier P. Pancreatic adenocarcinoma: ESMO-ESDO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23(Suppl 7):vii33–40.
   PubMedGoogle Scholar
• Pancreatic cancer in the UK. Lancet 2011;378:1050.
   Google Scholar
• Worni M, Guller U, White RR, Castleberry AW, Pietrobon R, Cerny T, et al. Modest improvement in overall survival for patients with metastatic pancreatic cancer: A trend analysis using the surveillance, epidemiology, and end results registry from 1988 to2008. Pancreas 2013;42: 1157–63.
   Google Scholar
• Baxter NN, Whitson BA, Tuttle TM. Trends in the treatment and outcome of pancreatic cancer in the United States. Ann Surg Oncol 2007;14:1320–6.
   PubMed Web of Science ®Google Scholar
• Sharp L, Carsin AE, Cronin-Fenton DP, O’Driscoll D, Comber H. Is there under-treatment of pancreatic cancer? Evidence from a population-based study in Ireland. Eur J Cancer 2009;45:1450–9.
   Web of Science ®Google Scholar
• De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Belot A, et al. The EUROCARE-4 database on cancer survival in Europe: Data standardisation, quality control and methods of statistical analysis. Eur J Cancer 2009;45: 909–30.
   PubMed Web of Science ®Google Scholar
• Bjerregaard JK, Mortensen MB, Schonnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer 2013;49:98–105.
   PubMed Web of Science ®Google Scholar
• Boyd CA, Benarroch-Gampel J, Sheffield KM, Cooksley CD, Riall TS. 415 patients with adenosquamous carcinoma of the pancreas: A population-based analysis of prognosis and survival. J Surg Res 2012;174:12–9.
   PubMed Web of Science ®Google Scholar
• Cress RD, Yin D, Clarke L, Bold R, Holly EA. Survival among patients with adenocarcinoma of the pancreas: A population-based study (United States). Cancer Causes Control 2006;17:403–9.
   PubMed Web of Science ®Google Scholar
• Burris HA, 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol 1997;15:2403–13.
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25: 1960–6.
   PubMed Web of Science ®Google Scholar
• Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: A randomised controlled trial. Lancet 2001;358:1576–85.
   PubMed Web of Science ®Google Scholar
• Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 2007;297:267–77.
   PubMed Web of Science ®Google Scholar
• Bernards N, Creemers GJ, Nieuwenhuijzen GA, Bosscha K, Pruijt JF, Lemmens VE. No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Ann Oncol 2013;24:3056–60.
   PubMed Web of Science ®Google Scholar
• Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: Population-based practices and effectiveness. J Clin Oncol 2003;21: 3409–14.
   PubMed Web of Science ®Google Scholar
• Cheung MC, Yang R, Byrne MM, Solorzano CC, Nakeeb A, Koniaris LG. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010;116:723–33.
   PubMed Web of Science ®Google Scholar
• National Working Group on Gastrointestinal Cancers. Guideline: Pancreatic cancer. The Netharlands: Comprehensive Cancer Centre; 2011.
   Google Scholar
• Schildmann J, Tan J, Salloch S, Vollmann J. ‘Well, I think there is great variation..’: a qualitative study of oncologists’ experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer. Oncologist 2013;18:90–6.
   PubMed Web of Science ®Google Scholar
• Sultana A, Smith CT, Cunningham D, Starling N, Neoptolemos JP, Ghaneh P. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. J Clin Oncol 2007;25:2607–15.
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New Engl J Med 2011;364: 1817–25.
   PubMed Web of Science ®Google Scholar
• Ko AH. FOLFIRINOX: A small step or a great leap forward? J Clin Oncol 2011:29:3727–9.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New Engl J Med 2013;369: 1691–703.
   PubMed Web of Science ®Google Scholar
• de Wilde RF, Besselink MG, van der Tweel I, de Hingh IH, van Eijck CH, Dejong CH, et al. Impact of nationwide centralization of pancreaticoduodenectomy on hospital mortality. Br J Surg 2011;99:404–10.
   Web of Science ®Google Scholar